Loading clinical trials...
Loading clinical trials...
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare FIAsp (faster-acting insulin aspart) to insulin aspart, both in combination with insulin glargine and metformin in adults with type 2 diabetes.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Novo Nordisk Investigational Site
Glendale, Arizona, United States
Novo Nordisk Investigational Site
Glendale, Arizona, United States
Novo Nordisk Investigational Site
Mesa, Arizona, United States
Novo Nordisk Investigational Site
Phoenix, Arizona, United States
Novo Nordisk Investigational Site
Tempe, Arizona, United States
Novo Nordisk Investigational Site
Anaheim, California, United States
Novo Nordisk Investigational Site
Fresno, California, United States
Novo Nordisk Investigational Site
Greenbrae, California, United States
Novo Nordisk Investigational Site
Lomita, California, United States
Novo Nordisk Investigational Site
Northridge, California, United States
Start Date
September 9, 2013
Primary Completion Date
January 22, 2015
Completion Date
January 22, 2015
Last Updated
January 30, 2019
881
ACTUAL participants
Faster-acting insulin aspart
DRUG
Insulin aspart
DRUG
Insulin glargine
DRUG
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07296484